The MILED Trial is a currently enrolling study led by Dr. Frank McCormack, Scientific Director of The LAM Foundation. The trial seeks to answer an important clinical question about early treatment of LAM. That question is: “Does early treatment of mild LAM symptoms with low dose sirolimus stop progression of disease and cyst formation in the lungs?” The answer to this question will benefit patients with LAM all around the world.
Here, we answer your own questions about the MILED Trial.
Gene Sullivan, MD, Emeritus Board Member of The LAM Foundation and former Deputy Director of the Division of Pulmonary and Allergy Products at the USFDA answers questions about the difference between generic and name brand drugs, specifically in regards to sirolimus and Rapamune.